Candida glabrata endophthalmitis treated successfully with caspofungin.
A 39-year-old man with Candida glabrata endophthalmitis was successfully treated with a 28-day course of intravenous caspofungin. Presence of underlying renal insufficiency and infection with a drug-resistant strain precluded use of amphotericin B or fluconazole. Intravitreal administration of antifungals and vitrectomy were not required. The role of caspofungin in Candida endophthalmitis is discussed.
Sarria
Juan C
JC
Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555-0435, USA. jcsarria@utmb.edu
Bradley
Jay C
JC
Habash
Ranya
R
Mitchell
Kelly T
KT
Kimbrough
Robert C
RC
Vidal
Ana M
AM
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D041221:Candida glabrata / Q000187:drug effects / Q000302:isolation & purification*; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D000077336:Caspofungin; D026141:Drug Resistance, Multiple, Fungal; D054714:Echinocandins; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D006801:Humans; D055666:Lipopeptides; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin